National Research Institute of Chinese Medicine, Ministry of Health and Welfare, No.155-1, Section 2, Linong Street, Beitou District, Taipei 11221, Taiwan; Ph.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, No. 250 Wu-Xing Street, Taipei 11031, Taiwan.
Department of Chinese Medicine, Tri-Service General Hospital, National Defense Medical Center, No.325, Section 2, Chenggong Road, Neihu District, Taipei 11490, Taiwan.
Biomed Pharmacother. 2021 Jan;133:111037. doi: 10.1016/j.biopha.2020.111037. Epub 2020 Nov 19.
COVID-19 is a global pandemic, with over 50 million confirmed cases and 1.2 million deaths as of November 11, 2020. No therapies or vaccines so far are recommended to treat or prevent the new coronavirus. A novel traditional Chinese medicine formula, Taiwan Chingguan Yihau (NRICM101), has been administered to patients with COVID-19 in Taiwan since April 2020. Its clinical outcomes and pharmacology have been evaluated. Among 33 patients with confirmed COVID-19 admitted in two medical centers, those (n = 12) who were older, sicker, with more co-existing conditions and showing no improvement after 21 days of hospitalization were given NRICM101. They achieved 3 consecutive negative results within a median of 9 days and reported no adverse events. Pharmacological assays demonstrated the effects of the formula in inhibiting the spike protein/ACE2 interaction, 3CL protease activity, viral plaque formation, and production of cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-α. This bedside-to-bench study suggests that NRICM101 may disrupt disease progression through its antiviral and anti-inflammatory properties, offering promise as a multi-target agent for the prevention and treatment of COVID-19.
截至 2020 年 11 月 11 日，COVID-19 已在全球大流行，确诊病例超过 5000 万例，死亡超过 120 万例。目前尚无推荐的治疗或预防新冠病毒的疗法或疫苗。一种新型的中药配方——台湾清冠一号（NRICM101）自 2020 年 4 月起就在台湾用于治疗 COVID-19 患者。已对其临床疗效和药理学进行了评估。在两个医疗中心收治的 33 例确诊 COVID-19 患者中，对年龄较大、病情较重、合并症较多且住院 21 天后无改善的患者（n=12）给予 NRICM101。他们在中位数为 9 天内连续 3 次检测结果为阴性，且未报告不良反应。药理检测表明，该配方具有抑制刺突蛋白/ACE2 相互作用、3CL 蛋白酶活性、病毒斑块形成以及白细胞介素（IL）-6 和肿瘤坏死因子（TNF）-α产生的作用。这项从床边到临床的研究表明，NRICM101 可能通过其抗病毒和抗炎特性来阻止疾病进展，有望成为 COVID-19 预防和治疗的多靶点药物。
